J Thromb Haemost: Clinical history of cancer-related visceral venous thrombosis

Cancer is a risk factor for visceral venous thrombosis (SVT) and common site venous thromboembolism (VTE).
recently, a study published in Journal of Thrombosis and Haemostasis, an authoritative journal of thrombosis and clotting diseases, aims to compare the characteristics and outcomes of cancer-related SVT and conventional site VTE patients.
researchers recruited physical cancer and SVT patients from the International Prospective Register study between May 2008 and January 2012.
comparison team included solid cancer patients and patients who received routine VTE treatment in a 1-to-1 ratio, who received at least 12 months of follow-up before December 2019, or one of the outcomes occurred during 12 months of follow-up.
12-month follow-up, the researchers assessed relapsed VTE, haemorrhage, and all-cause mortality.
264 patients (132 in each group) were in the group, SVT patients were less likely to develop metastasis (36.1% vs. 72.5%) or receive cancer treatment at the time of diagnosis of thrombosis (29.6% vs. 64.9%).
the most common types of cancer in the SVT patients' queue were liver and bile and pancreatic cancer, and the most common type of gastrointestinal cancer in the VTE patients' queue.
SVT patients who received anticoagulant therapy (68.9% vs. 99.2%) and had shorter treatment times (6.0 vs. 11.0 months).
In the SVT patient queue, the cumulative rate of haemorrhage (2.3% vs. 4.7%) was significantly lower, while relapsed thrombosis (4.7% vs. 5.5%) and all-cause mortality (41.7% vs. 39.4%) were comparable in both queues.
thus, although there are some differences between baseline characteristics and anticoagulant therapy, the risk of recurrence of thrombosis and bleeding appears to be similar in patients with SVT cancer and cancer patients with conventional VTE.
further forward-looking studies are needed to confirm these results.
。